Douglas Williams, Ph.D. has served as a member of our board of directors since January 2016. Dr. Williams is currently a member on the board of directors of each of Ironwood Pharmaceuticals, Inc. and Regulus Therapeutics Inc., each a publicly held biotechnology company. Dr. Williams is president, chief executive officer and a member of the board of directors of Codiak Biosciences, Inc., a biotechnology company, which was founded in November 2015. Prior to that, he served as Biogen Inc.’s executive vice president, research and development from January 2011 to July 2015. From 2004 to 2010, Dr. Williams served in various roles at ZymoGenetics, Inc., a former publicly held pharmaceutical company, and a subsidiary of Bristol-Myers Squibb Company, a publicly held pharmaceutical company, most recently in the role of chief executive officer and a member of its board of directors. Dr. Williams also served as a member of the board of directors of each of Oncothyreon Inc. and Array BioPharma Inc. Previously, Dr. Williams held senior leadership positions within the biotechnology industry, including chief scientific officer and executive vice president of research and development at Seattle Genetics, Inc., a publicly held biotechnology company, senior vice president and Washington site leader at Amgen, Inc., a publicly held biopharmaceutical company, and executive vice president and chief technology officer at Immunex Corporation, a publicly held pharmaceutical company, which was acquired by Amgen Inc. in 2002. Dr. Williams earned his B.S. in biological sciences from the University of Massachusetts, Lowell and his Ph.D. in physiology from the State University of New York at Buffalo, Roswell Park Memorial Institute Division.

PHYSIOLOGY,BIOTECHNOLOGY